For decades, testosterone replacement therapy (TRT) has been formally approved by the U.S. Food and Drug Administration only for men with classical hypogonadism, meaning low testosterone caused by a clear medical condition such as a testicular injury, pituitary disorder, or genetic syndrome. In April 2026, that long standing limit took a notable step toward changing.
What the FDA Announced
On April 20, 2026, the FDA published a Federal Register notice titled "Potential New Indication for Testosterone Replacement Therapy" (Federal Register, 2026). In it, the agency acknowledged that emerging clinical evidence supports a possible new use for TRT: treating low libido in men with idiopathic hypogonadism, a condition where testosterone levels are low without an identifiable structural or genetic cause.
The notice invites holders of approved TRT new drug applications (NDAs) to contact the agency by April 30, 2026, about submitting a supplemental NDA for this new indication (FDA, 2026). In plain language, the FDA is signaling that drugmakers can now begin the process of formally adding low libido to the list of approved uses for testosterone products.
How We Got Here
The April notice did not come out of nowhere. In December 2025, an FDA expert panel reviewed years of clinical data on TRT, including the landmark TRAVERSE cardiovascular safety trial. The panel recommended easing several restrictions on testosterone therapy, including the removal of TRT's status as a controlled substance and a broadening of the patient population eligible for treatment (RAPS, 2025).
That recommendation followed a February 2025 FDA decision to remove the cardiovascular black box warning from testosterone product labels, a warning that had discouraged many physicians and patients from pursuing therapy since 2015 (Healthline, 2025).
Who Could Benefit
If the new indication is formally approved, men with low testosterone and low libido but no identifiable cause of their hormone deficiency would have a clearly approved reason to seek TRT. Today, those patients often receive treatment off label, which can create insurance coverage challenges and inconsistent care.
The change would not turn testosterone into a lifestyle drug. The FDA still expects evidence of clinically low testosterone confirmed by morning blood draws, and the new indication would be tied specifically to symptomatic low libido.
